Author’s response to reviews

Title: A double-blinded, randomized, placebo-controlled intervention trial of 3mg and 10mg sublingual Melatonin for Post-Concussion Syndrome in Youth (PlayGame Trial).

Authors:

Karen M Barlow (kmbarlow@me.com)
Brian Brooks (brian.brooks@albertahealthservices.ca)
Frank MacMaster (fmacmast@ucalgary.ca)
Adam Kirton (adam.kirton@albertahealthservices.ca)
Trevor A Seeger (tadam.sgr@gmail.com)
Michael Esser (michael.esser@albertahealthservices.ca)
Susan Crawford (susan.crawford@albertahealthservices.ca)
Alberto Netel-Aguirre (alberto.netel-aguirre@albertahealthservices.ca)
Roger Zemek (RZemek@cheo.on.ca)
Mikrogianakis Angelo (Angelo.Mikrogianakis@albertahealthservices.ca)
Valerie Kirk (val.kirk@albertahealthservices.ca)
Carolyn Emery (caemery@ucalgary.ca)
David Johnson (david.johnson@albertahealthservices.ca)
Michael Hill (hillmd@ucalgary.ca)
Jeff Buchhalter (jeff.buchhalter@albertahealthservices.ca)
Brenda Turley (brenda.turley@albertahealthservices.ca)
Lawrence Richer (lricher@ualberta.ca)
Robert Platt (robert.platt@mcgill.ca)
Jamie Hutchison (jamie.hutchison@sickkids.ca)
Deborah Dewey (deborah.dewey@albertahealthservices.ca)

Version: 3
Date: 29 May 2014

Author’s response to reviews: see over
Dear Sir/Madam,

PLAYGAME trial: study protocol for a randomized controlled trial

I am delighted to submit the requested revisions for this study protocol.

I have added the requested details to the sample size calculation “We used data obtained in our epidemiological study to calculate a reliable change score using the Jackson-Truax method [2]. A 10-point change on the PCSI-P score indicates a reliable change for subjects who are symptomatic at one month (standard deviation 14.7).”

Many thanks

Yours sincerely,

Dr. Karen Barlow
MBChB MRCPCH(UK) MRCP (UK)